Highlights: -SWAN trial: Screening women for aneurysms would yield little benefit and not be cost-effective -EVAR 2 very long-term results prompt a call for shared decision-making in frail patients -Interim data from randomised trial show no benefit of liberation therapy in multiple sclerosis patients -Lars Lönn: Competence in EVAR -Barry Katzen: Critical limb ischaemia -Profile: Maarit Venermo
[pdfviewer width=”100%” height=”940px” beta=”true”]https://vascularnews.com/wp-content/uploads/sites/7/2017/06/VN-74-US.pdf[/pdfviewer]
